CO2019001871A2 - Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres. - Google Patents
Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres.Info
- Publication number
- CO2019001871A2 CO2019001871A2 CONC2019/0001871A CO2019001871A CO2019001871A2 CO 2019001871 A2 CO2019001871 A2 CO 2019001871A2 CO 2019001871 A CO2019001871 A CO 2019001871A CO 2019001871 A2 CO2019001871 A2 CO 2019001871A2
- Authority
- CO
- Colombia
- Prior art keywords
- autoimmune
- cancers
- treatment
- inflammatory diseases
- imidazole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de fórmula (I) y sales de los mismos: en la que R1, R2, R3 y a son como se definen en el presente documento. Se ha descubierto que los compuestos de fórmula (I) y sales de los mismos inhiben la unión de la familia BET de proteínas que contienen bromodominios a, por ejemplo, residuos de lisina acetilados y, por tanto, pueden tener uso en terapia, por ejemplo, en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide; y cánceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1614934.6A GB201614934D0 (en) | 2016-09-02 | 2016-09-02 | Chemical compounds |
PCT/EP2017/071868 WO2018041947A1 (en) | 2016-09-02 | 2017-08-31 | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019001871A2 true CO2019001871A2 (es) | 2019-03-08 |
Family
ID=57140084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0001871A CO2019001871A2 (es) | 2016-09-02 | 2019-02-27 | Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20190175571A1 (es) |
EP (1) | EP3507283A1 (es) |
JP (1) | JP2019526577A (es) |
KR (1) | KR20190042701A (es) |
CN (1) | CN109790147A (es) |
AR (1) | AR109487A1 (es) |
AU (1) | AU2017317724A1 (es) |
BR (1) | BR112019004241A2 (es) |
CA (1) | CA3035312A1 (es) |
CL (1) | CL2019000538A1 (es) |
CO (1) | CO2019001871A2 (es) |
CR (1) | CR20190106A (es) |
DO (1) | DOP2019000047A (es) |
EA (1) | EA201990410A1 (es) |
GB (1) | GB201614934D0 (es) |
JO (1) | JOP20190029A1 (es) |
MA (1) | MA46085A (es) |
MX (1) | MX2019002491A (es) |
PE (1) | PE20190478A1 (es) |
PH (1) | PH12019500460A1 (es) |
SG (1) | SG11201901673SA (es) |
TW (1) | TW201817724A (es) |
UY (1) | UY37393A (es) |
WO (1) | WO2018041947A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3507291T3 (da) | 2016-09-02 | 2021-08-30 | Cyclerion Therapeutics Inc | Kondenserede bicykliske sgc-stimulatorer |
CN111686114B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途 |
CN111588721B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途 |
CN111588725B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途 |
CN111686107B (zh) * | 2020-07-16 | 2021-06-08 | 中国农业科学院兰州兽医研究所 | 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途 |
WO2024018423A1 (en) * | 2022-07-21 | 2024-01-25 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
CN117257964B (zh) * | 2023-10-25 | 2024-04-02 | 苏州大学 | 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3406329A1 (de) * | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
DE4034060A1 (de) * | 1990-10-26 | 1992-04-30 | Basf Ag | Biskationische azofarbstoffe |
DE19809994B4 (de) * | 1997-03-19 | 2006-02-09 | Basf Ag | Clathrate von Bis-[6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(phen-4-ylazo)-pyridin-2-on]ethylen |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
PT2090570E (pt) * | 2006-09-05 | 2011-12-29 | Kyowa Hakko Kirin Co Ltd | Derivado de imidazole |
EP2274300A2 (en) * | 2008-03-21 | 2011-01-19 | Novartis AG | Novel heterocyclic compounds and uses therof |
JP5627574B2 (ja) * | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
MX2012010188A (es) * | 2010-03-04 | 2012-10-03 | Merck Sharp & Dohme | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. |
AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
-
2016
- 2016-09-02 GB GBGB1614934.6A patent/GB201614934D0/en not_active Ceased
-
2017
- 2017-06-16 JO JOP/2019/0029A patent/JOP20190029A1/ar unknown
- 2017-08-31 UY UY0001037393A patent/UY37393A/es not_active Application Discontinuation
- 2017-08-31 JP JP2019511919A patent/JP2019526577A/ja active Pending
- 2017-08-31 MA MA046085A patent/MA46085A/fr unknown
- 2017-08-31 EA EA201990410A patent/EA201990410A1/ru unknown
- 2017-08-31 CN CN201780059730.0A patent/CN109790147A/zh active Pending
- 2017-08-31 TW TW106129714A patent/TW201817724A/zh unknown
- 2017-08-31 SG SG11201901673SA patent/SG11201901673SA/en unknown
- 2017-08-31 MX MX2019002491A patent/MX2019002491A/es unknown
- 2017-08-31 CR CR20190106A patent/CR20190106A/es unknown
- 2017-08-31 BR BR112019004241A patent/BR112019004241A2/pt not_active Application Discontinuation
- 2017-08-31 KR KR1020197009266A patent/KR20190042701A/ko not_active Application Discontinuation
- 2017-08-31 AU AU2017317724A patent/AU2017317724A1/en not_active Abandoned
- 2017-08-31 CA CA3035312A patent/CA3035312A1/en not_active Abandoned
- 2017-08-31 AR ARP170102425A patent/AR109487A1/es unknown
- 2017-08-31 WO PCT/EP2017/071868 patent/WO2018041947A1/en unknown
- 2017-08-31 EP EP17758878.7A patent/EP3507283A1/en not_active Withdrawn
- 2017-08-31 PE PE2019000455A patent/PE20190478A1/es unknown
- 2017-08-31 US US16/326,991 patent/US20190175571A1/en not_active Abandoned
-
2019
- 2019-02-27 CO CONC2019/0001871A patent/CO2019001871A2/es unknown
- 2019-02-28 DO DO2019000047A patent/DOP2019000047A/es unknown
- 2019-02-28 CL CL2019000538A patent/CL2019000538A1/es unknown
- 2019-03-01 PH PH12019500460A patent/PH12019500460A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2017317724A1 (en) | 2019-03-21 |
EA201990410A1 (ru) | 2019-09-30 |
UY37393A (es) | 2018-03-23 |
AR109487A1 (es) | 2018-12-12 |
TW201817724A (zh) | 2018-05-16 |
DOP2019000047A (es) | 2019-03-15 |
GB201614934D0 (en) | 2016-10-19 |
MX2019002491A (es) | 2019-07-08 |
JOP20190029A1 (ar) | 2019-02-25 |
PE20190478A1 (es) | 2019-04-04 |
EP3507283A1 (en) | 2019-07-10 |
JP2019526577A (ja) | 2019-09-19 |
CR20190106A (es) | 2019-05-02 |
SG11201901673SA (en) | 2019-03-28 |
KR20190042701A (ko) | 2019-04-24 |
CL2019000538A1 (es) | 2019-05-17 |
WO2018041947A1 (en) | 2018-03-08 |
BR112019004241A2 (pt) | 2019-06-04 |
CA3035312A1 (en) | 2018-03-08 |
MA46085A (fr) | 2019-07-10 |
CN109790147A (zh) | 2019-05-21 |
PH12019500460A1 (en) | 2019-12-16 |
US20190175571A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002332A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
CO2019001871A2 (es) | Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres. | |
CO2017011484A2 (es) | Inhibidores de bromodominio | |
CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
CY1121850T1 (el) | Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων | |
CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
CR20160229A (es) | Inhibidires de bromodominio | |
CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
CU20170162A7 (es) | Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
BR112012023752A2 (pt) | derivados de pirrolopirazina e seu uso como inibidores de jak e syk | |
BR112016001645A8 (pt) | derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit | |
CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
UY35610A (es) | Derivados de prodroga de triazolpiridinas sustituidas |